Session » Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1639

A Comparison of Cardiovascular Health Indicators in Children with Juvenile Idiopathic Arthritis Who Meet and Do Not Meet the Physical Activity Guidelines

8:30AM-10:30AM: Abstract Number: 1616

Acceptability of COVID-19 Vaccine Among Pediatric Rheumatology Patients in California’s Central Valley

8:30AM-10:30AM: Abstract Number: 1642

Baseline Body-mass-index and Risk for Obesity in Children with Rheumatic Disease on Moderate to High-dose Prednisone Therapy

8:30AM-10:30AM: Abstract Number: 1617

Burden of Adverse Childhood Experiences in Pediatric Chronic Pain and Rheumatic Disease

8:30AM-10:30AM: Abstract Number: 1625

Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort

8:30AM-10:30AM: Abstract Number: 1632

Clinical Features and Colchicine Response in Patients with Undifferentiated Systemic Autoinflammatory Disease Carrying E148Q vs. Other MEFV Mutations

8:30AM-10:30AM: Abstract Number: 1638

Clinical Manifestations of COVID-19 and Its Impact on Pediatric Patients with Rheumatic Disease

8:30AM-10:30AM: Abstract Number: 1637

Covid-19 Infection Among Pediatric Rheumatology Patients: A Single Center Experience

8:30AM-10:30AM: Abstract Number: 1618

Disease Flares in CANDLE/PRAAS with Dose Reductions of Baricitinib

8:30AM-10:30AM: Abstract Number: 1629

Effect of Drug Withdrawal on Interleukin-1 or Interleukin-6 Inhibitor Associated Diffuse Lung Disease

8:30AM-10:30AM: Abstract Number: 1633

Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review

8:30AM-10:30AM: Abstract Number: 1623

Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada

8:30AM-10:30AM: Abstract Number: 1643

Increased Incidence of Pediatric SLE and Other Interferon Activated Diseases During COVID-19 Pandemic

8:30AM-10:30AM: Abstract Number: 1627

Long Term Follow-Up of Patients with Childhood-Onset Lupus Nephritis After Transition to Adult Care

8:30AM-10:30AM: Abstract Number: 1641

Long-term Cardiovascular Disease and Mortality Following Kawasaki Disease in Childhood: A Systematic Review

8:30AM-10:30AM: Abstract Number: 1622

Mind the Gap: The Experience of Adolescents in a Rheumatology Transition Clinic

8:30AM-10:30AM: Abstract Number: 1640

Multisystem Inflammatory Syndrome in Children at Two Tertiary Hospitals in Cape Town, South Africa: Clinical Phenotype and Distinguishing Features from Similar Acute Inflammatory Conditions

8:30AM-10:30AM: Abstract Number: 1630

Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization

8:30AM-10:30AM: Abstract Number: 1635

Nailfold Capillary Microscopy in Children with Raynaud’s Phenomenon. Potential Predictive Value of Capillary Loss for Future Connective Tissue Disease?

8:30AM-10:30AM: Abstract Number: 1634

Patient Activation and Health Literacy in the Pediatric to Adult Transition in Juvenile Systemic Lupus Erythematosus: Patient and Health Care Team Perspectives

8:30AM-10:30AM: Abstract Number: 1624

Patient-Reported Care Utilization, Socioeconomic Status, and Health Status Among Young Adults with JIA

8:30AM-10:30AM: Abstract Number: 1620

Pediatric Onset (< 16 Years) Non-infectious Uveitis: Results from Spanish National Registry

8:30AM-10:30AM: Abstract Number: 1636

Pediatric Rheumatologists’ Perspectives on Diagnosis, Treatment and Outcomes of Sjögren Syndrome in Children and Adolescents

8:30AM-10:30AM: Abstract Number: 1631

Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis

8:30AM-10:30AM: Abstract Number: 1614

Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain

8:30AM-10:30AM: Abstract Number: 1628

Reproductive Health Knowledge Gaps, Needs, and Barriers Identified by Pediatric Rheumatology Providers

8:30AM-10:30AM: Abstract Number: 1615

Responsiveness of Quality of Life and Function Assessment to Changes in Topical Eye Medications in Children with Uveitis

8:30AM-10:30AM: Abstract Number: 1621

Self-reported Transition Readiness of Adolescent Patients with Rheumatologic Disease: Do the Parents Agree?

8:30AM-10:30AM: Abstract Number: 1644

Storytelling of Young Adults with Chronic Rheumatologic Illnesses: A Pilot Study

8:30AM-10:30AM: Abstract Number: 1626

Use of Total Hip Arthroplasty in Patients Under 21 Years Old: A U.S. Population Analysis

8:30AM-10:30AM: Abstract Number: 1619

Where Do Multisystem Inflammatory Syndrome in Children (MIS-C) and Pediatric COVID-19 Fit Under the Cytokine Storm Syndrome Umbrella?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].